際際滷

際際滷Share a Scribd company logo

Tes mobile startupvillage

Download as PPTX, PDF
Ksenia Gorbunova
Ksenia Gorbunova

The document outlines plans to develop and launch a line of medical devices and mobile applications to treat sensorineural hearing loss and tinnitus using a proprietary technology called Audioselective Transcranial Electric Stimulation (ATES). Clinical trials showed ATES improved hearing in 67-89% of patients and reduced tinnitus symptoms in 91% of patients. The proposed business model and market analysis indicate the ATES devices could generate over $21 million in sales revenue within 6 years by targeting the growing markets for hearing aids and mobile medical devices.

1 of 10
Download to read offline
TES MOBILE 1 Development, creation and international launch of a line of medical devices to treat sensorineural hearing loss and tinnitus
SUMMARY Project aim: Development, certification and international market launch of a line of medical devices and a procedure to treat sensorineural hearing loss and tinnitus. Essence of the innovation: Implementing unique patented technology for selective transcranial electric stimulation of the brains protective mechanisms with an impulse current combined with acoustic influence by tonal signals. To be created during project realization: Professional and individual device versions; the latter will be in the form of a mobile application (for download and periodic update) and a special headset connected to users mobile platform (smartphone or tablet PC). Project budget (24 months): $ 1 335K Looking for: Partners for product promotion. 2
MEDICAL PROBLEM About 10 % of the worlds population suffer from hearing disorders In 2015 the number of patients will reach 700 million and there will be 900 million patients in 2020 85-90 % of patients have sensorineural hearing loss and 50 % have tinnitus This equals 30 million patients in the US, 80 million in Europe and 13 million in Russia Hearing loss and tinnitus have no specific treatment at present! 3
THE SOLUTION Audioselective Transcranial Electric Stimulation Audio stimuli of variable Transcranial Electric frequency and intensity Stimulation The biophysical basis is the proven positive impact of re-education in the treatment of acoustic neuronal disorders Professional Individual 4
PROTOTYPE AND RESULTS Prototype device TRANSAIR-07. Course 10-15 procedures, every other day. Results: Hearing improved in 89 % of patients with acute/sudden hearing loss and in 67 % of those with chronic hearing loss (regardless of etiology) Tinnitus stops or becomes milder in 91 % of patients Tonal hearing thresholds are stably decreased by 10- 35 dB Percentage of patients with improved hearing ATES effects on subjective tinnitus in acute and chronic SNHL 9% 36% 55% 5 Tinnitus stopped Tinnitus decreased in intensity Tinnitus remained unchanged
COMPETITIVE TECHNOLOGIES Traditional drug and Tinnitus Retaining Cochlear implants physical therapy Therapy (TRT) These implants consist Histamine-like Use of special hearing devices of wearable (external) and medicines, retroauricular procaine combined with white noise implanted (inner) parts. The costs blocks, laser therapy, stimulation generator. Widely used in the of an operation start from USD with fluctuating current, quantum West, with a sales volume (therapy 30,000. The market has topped hemotherapy, plasmapheresis, ho courses) in 2011 exceeding USD 87 USD 960 million and will reach meopathic medicines, etc. million. USD 2.3 billion in 2017. The USA accounts for 40 % of the market. Does not treat the Invasive hearing Aimed to inhibit disease disease, but teaches the restoration applicable progression, not to treat patient in severe hearing loss it to ignore it only 6
BUSINESS MODEL: Individual ATES purchase recommendation 4P Insurance coverage Purchase of SW updates fee 7
BUSINESS MODEL: Professional ATES Equipment and service consumables at wholesale price sale Equipment and consumables at market price 8
MARKET AND SALES The market for hearing aids grows by 10-15 % a year, to reach USD 26.2 billion in 2017* USA, Europe, Canada, and Japan account for 80 % of sales. Within the last 5 years, the mobile device market in the US tripled (from USD 2.7 billion to 9.6 billion); 15 million devices were sold** Sales volume in 6yr. (est.) $ 21,6M 1.4 % 0.1 % 仂亟舒亢舒 亳仆亟亳于亳亟舒仍仆 丐亅弌 (弍亠亰coverage) Sales of individual ATES (without insurance 舒仂于仂亞仂 仗仂从亳) Sales of individual ATES (with insurance coverage) 仂亟舒亢舒 亳仆亟亳于亳亟舒仍仆 丐亅弌 (仂 舒仂于仄 仗仂从亳亠仄) 23.1 % 亠舒仍亳亰舒亳 仗仂亠亳仂仆舒仍仆 丐亅弌 Sales of professional ATES 34.4 % 仂仄亳亳 仍亞亳 仗仂 仍亠亠仆亳 弌丐 亳 Fees per services in SNHL and tinnitus treatment 亳仆仆亳舒 仂亟舒亢舒 仂弍仆仂于仍亠仆亳亶 for individual ATES Sales of software updates 亟仍 37.0 % 亳仆亟亳于亳亟舒仍仆仂亞仂 丐亅弌 3.9 % 仂亟舒亢舒 舒仂亟仆 仄舒亠亳舒仍仂于 亟仍 Sales of consumables for professional ATES 仗仂亠亳仂仆舒仍仆仂亞仂 丐亅弌 * - Audiological Devices - Global Strategic Business Report ** - HIMSS Analytics 9
THE TEAM Alexander Malygin CEO, co-founder, Candidate of Technical Science, MBA, 20 years of business experience. He headed the organization of serial production, certification and technical testing of TRANSAIR and DOKTOR TES devices, participated in creating a sales and service network for the device. During his job, more than 5,000 and over 40,000 TRANSAIR and DOKTOR TES devices respectively have been sold and 10 regional agencies have been founded. Prof. Valeriy Lebedev Research Director, MD, co-founder, member of the Russian Academy of Natural Sciences. He discovered TES effects on protective systems in the brain of animals and humans. The author of 98 articles and 115 theses on TES therapy. An Honored Science Worker of the Russian Federation and Head of Applied Neurophysiology at the I.M. Sechenov Saint Petersburg Society of Physiologists, Biochemists and Pharmacologists. Anna Belimova physical therapist and audiologist, Candidate of Medicine, 10 years of experience in SNHL treatment. She has personally performed all clinical trials, arranged and partly performed instrumental testing, carried out ATES procedures in SNHL patients, and studied changes in hearing after ATES. Dmitry Tseitlin Business Development Director, MD, Candidate of Medicine, 20 years of experience in international marketing and technology commercialization in Russia, Israel and Germany. Business Coach at the Skolkovo Industrial Park. 10

More Related Content

Tes mobile startupvillage

  • 1. TES MOBILE 1 Development, creation and international launch of a line of medical devices to treat sensorineural hearing loss and tinnitus
  • 2. SUMMARY Project aim: Development, certification and international market launch of a line of medical devices and a procedure to treat sensorineural hearing loss and tinnitus. Essence of the innovation: Implementing unique patented technology for selective transcranial electric stimulation of the brains protective mechanisms with an impulse current combined with acoustic influence by tonal signals. To be created during project realization: Professional and individual device versions; the latter will be in the form of a mobile application (for download and periodic update) and a special headset connected to users mobile platform (smartphone or tablet PC). Project budget (24 months): $ 1 335K Looking for: Partners for product promotion. 2
  • 3. MEDICAL PROBLEM About 10 % of the worlds population suffer from hearing disorders In 2015 the number of patients will reach 700 million and there will be 900 million patients in 2020 85-90 % of patients have sensorineural hearing loss and 50 % have tinnitus This equals 30 million patients in the US, 80 million in Europe and 13 million in Russia Hearing loss and tinnitus have no specific treatment at present! 3
  • 4. THE SOLUTION Audioselective Transcranial Electric Stimulation Audio stimuli of variable Transcranial Electric frequency and intensity Stimulation The biophysical basis is the proven positive impact of re-education in the treatment of acoustic neuronal disorders Professional Individual 4
  • 5. PROTOTYPE AND RESULTS Prototype device TRANSAIR-07. Course 10-15 procedures, every other day. Results: Hearing improved in 89 % of patients with acute/sudden hearing loss and in 67 % of those with chronic hearing loss (regardless of etiology) Tinnitus stops or becomes milder in 91 % of patients Tonal hearing thresholds are stably decreased by 10- 35 dB Percentage of patients with improved hearing ATES effects on subjective tinnitus in acute and chronic SNHL 9% 36% 55% 5 Tinnitus stopped Tinnitus decreased in intensity Tinnitus remained unchanged
  • 6. COMPETITIVE TECHNOLOGIES Traditional drug and Tinnitus Retaining Cochlear implants physical therapy Therapy (TRT) These implants consist Histamine-like Use of special hearing devices of wearable (external) and medicines, retroauricular procaine combined with white noise implanted (inner) parts. The costs blocks, laser therapy, stimulation generator. Widely used in the of an operation start from USD with fluctuating current, quantum West, with a sales volume (therapy 30,000. The market has topped hemotherapy, plasmapheresis, ho courses) in 2011 exceeding USD 87 USD 960 million and will reach meopathic medicines, etc. million. USD 2.3 billion in 2017. The USA accounts for 40 % of the market. Does not treat the Invasive hearing Aimed to inhibit disease disease, but teaches the restoration applicable progression, not to treat patient in severe hearing loss it to ignore it only 6
  • 7. BUSINESS MODEL: Individual ATES purchase recommendation 4P Insurance coverage Purchase of SW updates fee 7
  • 8. BUSINESS MODEL: Professional ATES Equipment and service consumables at wholesale price sale Equipment and consumables at market price 8
  • 9. MARKET AND SALES The market for hearing aids grows by 10-15 % a year, to reach USD 26.2 billion in 2017* USA, Europe, Canada, and Japan account for 80 % of sales. Within the last 5 years, the mobile device market in the US tripled (from USD 2.7 billion to 9.6 billion); 15 million devices were sold** Sales volume in 6yr. (est.) $ 21,6M 1.4 % 0.1 % 仂亟舒亢舒 亳仆亟亳于亳亟舒仍仆 丐亅弌 (弍亠亰coverage) Sales of individual ATES (without insurance 舒仂于仂亞仂 仗仂从亳) Sales of individual ATES (with insurance coverage) 仂亟舒亢舒 亳仆亟亳于亳亟舒仍仆 丐亅弌 (仂 舒仂于仄 仗仂从亳亠仄) 23.1 % 亠舒仍亳亰舒亳 仗仂亠亳仂仆舒仍仆 丐亅弌 Sales of professional ATES 34.4 % 仂仄亳亳 仍亞亳 仗仂 仍亠亠仆亳 弌丐 亳 Fees per services in SNHL and tinnitus treatment 亳仆仆亳舒 仂亟舒亢舒 仂弍仆仂于仍亠仆亳亶 for individual ATES Sales of software updates 亟仍 37.0 % 亳仆亟亳于亳亟舒仍仆仂亞仂 丐亅弌 3.9 % 仂亟舒亢舒 舒仂亟仆 仄舒亠亳舒仍仂于 亟仍 Sales of consumables for professional ATES 仗仂亠亳仂仆舒仍仆仂亞仂 丐亅弌 * - Audiological Devices - Global Strategic Business Report ** - HIMSS Analytics 9
  • 10. THE TEAM Alexander Malygin CEO, co-founder, Candidate of Technical Science, MBA, 20 years of business experience. He headed the organization of serial production, certification and technical testing of TRANSAIR and DOKTOR TES devices, participated in creating a sales and service network for the device. During his job, more than 5,000 and over 40,000 TRANSAIR and DOKTOR TES devices respectively have been sold and 10 regional agencies have been founded. Prof. Valeriy Lebedev Research Director, MD, co-founder, member of the Russian Academy of Natural Sciences. He discovered TES effects on protective systems in the brain of animals and humans. The author of 98 articles and 115 theses on TES therapy. An Honored Science Worker of the Russian Federation and Head of Applied Neurophysiology at the I.M. Sechenov Saint Petersburg Society of Physiologists, Biochemists and Pharmacologists. Anna Belimova physical therapist and audiologist, Candidate of Medicine, 10 years of experience in SNHL treatment. She has personally performed all clinical trials, arranged and partly performed instrumental testing, carried out ATES procedures in SNHL patients, and studied changes in hearing after ATES. Dmitry Tseitlin Business Development Director, MD, Candidate of Medicine, 20 years of experience in international marketing and technology commercialization in Russia, Israel and Germany. Business Coach at the Skolkovo Industrial Park. 10